Previous 10 | Next 10 |
CAMBRIDGE, Mass. and NEW YORK, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that Chairman of the Board of Directors, Robert (Bob) A. Ingram,...
Black Diamond Therapeutics ( NASDAQ: BDTX ) is trading ~8% higher premarket after the company said it had formed Launchpad Therapeutics, an antibody-focused precision oncology firm, with a $30M Series A investment by founding investors, Versant Ventures and New Enterprise Associat...
- $30M Series A investment from Versant Ventures and NEA- CAMBRIDGE, Mass. and NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announce...
Summary Shares of precision therapy concern Black Diamond Therapeutics, Inc. (BDTX) are down 90% from their IPO price, mostly due to scrapping its lead program before completing a Phase 1/2 trial. That leaves the company with one very early-stage clinical asset with no data due until 2H...
Black Diamond Therapeutics press release ( NASDAQ: BDTX ): Q3 GAAP EPS of -$0.60 beats by $0.04 . Cash, equivalents and investments of approximately $144.2 million as of September 30, 2022; expected to be sufficient to fund operations into the third quarter o...
Presented new data at the 34 th EORTC-NCI-AACR Symposium highlighting robust preclinical anti-tumor activity of BDTX-1535 and BDTX-4933 across multiple families of oncogenic mutations while sparing wild type; both MasterKey therapies demonstrate key attributes of next genera...
Insiders Play The Stock Market Game With Penny Stocks Want to find penny stocks to buy? How about trying the “Follow The Money” trend? It’s becoming more popular lately, especially in light of the recent stock market game being played. One day markets are up; th...
BDTX-1535 is an irreversible MasterKey inhibitor of multiple EGFR alterations that utilize similar activated oncogenic EGFR conformations to drive tumor cell growth in GBM and NSCLC BDTX-1535 demonstrated potent systemic and CNS anti-tumor activity and survival benefit in multip...
CAMBRIDGE, Mass. and NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Master Key therapies, today announced that its President and Chief Executive Officer, David M....
Black Diamond Therapeutics press release ( NASDAQ: BDTX ): Q2 GAAP EPS of -$0.63 beats by $0.07 . Black Diamond ended the second quarter of 2022 with approximately $160.9 million in cash, cash equivalents, and investments compared to $209.8 million as of December 31, 2...
News, Short Squeeze, Breakout and More Instantly...
Black Diamond Therapeutics Inc. Company Name:
BDTX Stock Symbol:
NASDAQ Market:
Black Diamond Therapeutics Inc. Website:
2024-07-31 09:00:12 ET Laura Prendergast from Raymond James issued a price target of $20.00 for BDTX on 2024-07-31 08:18:00. The adjusted price target was set to $20.00. At the time of the announcement, BDTX was trading at $5.91. The overall price target consensus is at ...
2024-06-17 20:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial data from Phase 0/1 “trigger” (“window of opportunity”) inves...